UCB Joins the Dermatology Community for #IFPAConference2024

The IFPA Conference 2024, also known as the 7th World Psoriasis and Psoriatic Arthritis Conference, is taking place this week in Stockholm, Sweden, June 27–29. Organized by the International Federation of Psoriatic Associations (IFPA), this conference is held every three years, and the 2024 edition marks the seventh occurrence. The theme of this year’s scientific gathering is “Uncovering the broad spectrum of psoriatic disease.”

UCB is committed to improving the lives of people living with psoriasis and psoriatic arthritis and is a proud diamond sponsor of this event. The conference will bring together clinical experts, healthcare professionals, researchers and advocacy organizations to share the latest research and updates on these immuno-dermatological conditions. The forum provides an excellent opportunity to facilitate the sharing of achievements as well as advancements in preventing, diagnosing, and treating psoriasis and psoriatic arthritis. Additionally, it allows for conversations about the interconnected co-morbidities that can impact patients’ lives.  

Psoriasis is a chronic immune-mediated inflammatory skin disease that affects over 125 million people worldwide. An estimated 30% of people living with psoriasis also develop psoriatic arthritis, a progressive inflammatory disease that can cause joint swelling, pain, and stiffness, potentially leading to irreversible joint damage if not properly managed. These diseases are multifaceted with significant physical, emotional and psychological burdens on all aspects of daily life. UCB has a long-standing commitment to developing solutions aimed at improving the lives of people with psoriasis and psoriatic arthritis.  

Here are some highlights of UCB’s presence at the IFPA Conference 2024: 

1. Scientific abstracts: UCB will present its latest research across seven abstracts with five focused on psoriasis and two focused on psoriatic arthritis.
2. Scientific symposium: UCB will host a scientific symposium entitled “Exploring the patients’ path: how can we raise the standard of care in psoriatic disease?’ on Friday 28th June between 12:15 and 13:15 CET. Leading opinion leaders will discuss and debate the latest developments in psoriasis and psoriatic arthritis.
3. Exhibition booth: Delegates can also visit the UCB exhibition booth to interact with the on-site UCB team and learn more about the immuno-dermatology portfolio. 

A key contributing factor to future advances in immuno-dermatology is collaboration and partnership with the global community. UCB is committed to maintaining deep connections with patients and the scientific community, to enable seamless knowledge sharing that drives improvements in the standard of care for people living with immuno-dermatological conditions.

The IFPA Conference 2024 promises to offer an enriching experience with clinically relevant discussions and a patient-centric approach. It also provides an inspiring forum to ignite meaningful conversations on raising the standards of care in psoriasis and psoriatic arthritis. If you are attending, connect with #TeamUCB on-site!

UCB has a proven heritage in immunology. We harness evidence-based science to deliver solutions and services that address persistent unmet needs across the healthcare ecosystem. By leveraging data, technology, and innovative scientific research, we aim to improve the lives of people living with these diseases.